Innovent announces 2nd BTD by NMPA for Olverembatinib for treatment of patients with SDH-deficient GIST

Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors

AstraZeneca receives CDSCO approval for Tremelimumab combination in India

Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)

Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy

Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada

Glenmark sets GHG emission targets for FY2035

The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock

Synexa Joins CEPI in advancing global epidemic preparedness and response

Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness

Janssen Tremfya excels as psoriasis treatment, outshining IL-17s, says GlobalData

The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab

Capnopharm receives CE certification for its new CapnoPen technology

Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745

Kristin Judge Joins Emmes as Chief Growth Officer

Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239

Roquette, Beren Therapeutics join forces to advance cyclodextrin technologies

Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.